Integrin alpha 7 expression in newly diagnosed Egyptian chronic lymphocytic leukemia patients | ||||
| Egyptian Journal of Cancer and Biomedical Research | ||||
| Volume 9, Issue 2, June 2025, Page 49-56 PDF (555.87 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jcbr.2025.359934.1384 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Sarah M. Nawar  1; Yasmin samir1; Asmaa Mahmoud2
| ||||
| 1Hematology Department, Medical Research Institute, Alexandria University, Alexandria, Egypt | ||||
| 2Internal Medicine (Hematology Unit), Faculty of Medicine, Alexandria University, Alexandria, Egypt | ||||
| Abstract | ||||
| Background: The landscape for chronic lymphocytic leukemia (CLL) has undergone a full makeover since the emergence of effective targeted therapies. Searching for novel biomarkers in CLL patients is critical to improve outcomes in CLL patients. Integrins, which play a key role in the tissue localization of both normal and malignant cells, are now known to be expressed in cells as well as in tumor and immune cell exosomes that can affect endothelial cells' proliferation, migration, and gene expression. Aim: Here, we aimed to assess the role of integrin α7 gene expression in de novo CLL patients. Materials and Methods: Integrin alpha7 gene expression by real-time PCR was evaluated in 40 De novo CLL patients as well as 40 age and sex-matched controls at the Medical Research Institute, Alexandria University, Egypt. Results: Levels of integrin α7 gene expression were significantly higher in CLL cases compared to normal controls. Conclusion: Integrin α7 gene expression can be used as a prognostic marker in de novo CLL patients. | ||||
| Keywords | ||||
| CLL; gene expression; Integrin α7 | ||||
|
Statistics Article View: 70 PDF Download: 40 |
||||
